NCT07620574Phase 3Enrolling by invitation

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Study sponsor: Exelixis

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2030-05-31Estimated

Enrollment · participants5000Estimated

Source updated2026-08-18Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-08-18 · 1 field changed

Recruitment status

Recorded edit

− Previous value

Not yet recruiting

+ Updated value

Enrolling by invitation

Check registry source

Study details

Conditions studied

Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET); Extra-Pancreatic NET (epNET); Hepatocellular Carcinoma (HCC); Differentiated Thyroid Cancer (DTC); Non-Clear Cell Renal Cell Carcinoma (nccRCC); Colorectal Cancer; Prostate Cancer

Treatments or interventions studied

CabozantinibDrugAlso known as XL184, Cabometyx
ZanzalintinibDrugAlso known as XL092
AtezolizumabDrug
NivolumabDrug
AbirateroneDrug
PrednisoneDrug
EnzalutamideDrug

Primary outcomes · main study measures

measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs); timeFrame: Up to 4 years (until the event resolves, returns to baseline, stabilizes, a new anticancer therapy is initiated, or the participant is lost to follow-up or withdraws consent, whichever occurs first)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history